Additional bedtime H2‐receptor antagonist for the control of nocturnal gastric acid breakthrough: A Cochrane systematic review

OBJECTIVES: To assess the effectiveness and safety of additional bedtime H₂‐receptor antagonists (H₂RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H₂RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H₂RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H₂RAs in suppressing NAB.     

静脉溶栓后冠状动脉再通与室壁瘤形成因素分析

目的分析室壁瘤形成的原因,探讨冠状动脉血管再通与溶拴距发病时间的关系,探讨静脉溶栓治疗的价值。方法接受尿激酶(UK)静脉溶栓治疗的40例首发急性心肌梗死为研究对象,分成冠状动脉再通组22例,未通组18例,通过心脏二维超声检查观察室壁瘤的形成、LVEF及各种严重并发症。溶栓距发病时间分为<6小时、6~12小时两组进行比较。结果室壁瘤再通组占4.5%(1/22),未通组占22%(4/16);溶拴距发病时间<6小时再通组占47.5%(19/40),6~12小时再通组占7.5%(3/40);LVEF再能组0.61±0.11,未通组0.45±0.11;各种严重并发症两组比较差异无显著性意义。结论室壁瘤的产生及LVEF与冠状动脉血管再通的成功与否有关,血管再通的效果与溶栓距发病时间有关。     

Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations.

Mutations in the gene encoding 11beta-hydroxysteroid dehydrogenase type 2, HSD11B2, cause a rare monogenic juvenile hypertensive syndrome called apparent mineralocorticoid excess (AME). In AME, defective HSD11B2 enzyme activity results in overstimulation of the mineralocorticoid receptor (MR) by cortisol, causing sodium retention, hypokalemia, and salt-dependent hypertension. Here, we have studied whether genetic variations in HDS11B2 are implicated in essential hypertension in Japanese hypertensives and the general population. By sequencing the entire coding region and the promoter region of HDS11B2 in 953 Japanese hypertensives, we identified five missense mutations in 11 patients (L14F, n = 5; R74H, n = 1; R147H, n = 3; T156I, n = 1; R335H, n = 1) and one novel frameshift mutation (4884Gdel, n = 1) in a heterozygous state, in addition to 19 genetic variations. All genetic variations identified were rare, with minor allele frequencies less than 0.005. Four of 12 patients with the missense/frameshift mutations showed renal failure. Four missense mutations, L14F, R74H, R147H, and R335H, were successfully genotyped in the general population, with a sample size of 3,655 individuals (2,175 normotensives and 1,480 hypertensives). Mutations L14F, R74H, R147H, and R335H were identified in hypertensives (n = 6, 8, 3, and 0, respectively) and normotensives (n = 8, 12, 5, and 0, respectively) with a similar frequency, suggesting that these missense mutations may not strongly affect the etiology of essential hypertension. Since the allele frequency of all of the genetic variations identified in this study was rare, an association study was not conducted. Taken together, our results indicate that missense mutations in HSD11B2 do not substantially contribute to essential hypertension in Japanese.     

应用64层CT一次扫描完成心脏冠脉成像及心功能分析的可行性初步研究

目的研究64层CT一次扫描同时完成心脏冠脉成像及心功能分析的可行性。方法96例患者均行MSCT心脏成像扫描和MR心脏检查,数据分别按照冠脉成像和心功能分析要求进行重建和后处理,评估。结果1271段冠脉血管中有约99%血管显示清晰,达到诊断要求;心功能分析数据左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、左室每搏输出量(LVSV)、左室射血分数(LVEF)、左室心肌容积(LVMV)与MR相关数据的相关系数分别为0.84、0.91、0.94、0.89、0.88。结论MSCT可以在一次扫描中完成冠脉成像和心功能数据采集,具有极高应用价值。     

高同型半胱氨酸血症与脑卒中相关性研究

目的探讨血浆同型半胱氨酸(H cy)水平对脑卒中临床亚型、复发及痴呆的影响,并研究高同型半胱氨酸血症(HH)与脑卒中传统危险因素之间的相关性。方法应用酶联免疫吸附试验(EL ISA)检测90例急性脑卒中患者血浆H cy水平。将研究对象分为不同临床亚型,脑白质损伤组与非脑白质损伤组,青年组与老年组,痴呆组与非痴呆组。对不同类型脑卒中患者血浆H cy水平进行比较,对HH脑卒中传统危险因素进行相关与回归分析。结果首次发作(FCS)组血浆H cy水平明显低于复发(RCS)组(P<0.01),HH发生率比较RCS组明显高于FCS组(P<0.05)。痴呆组血浆H cy水平与对照组有差别(P<0.01)。饮酒者血浆H cy含量明显高于不摄入酒精者(P<0.05)。结论HH是脑卒中的独立危险因素,脑卒中患者普遍存在HH,在复发性脑卒中患者中尤其明显。血浆H cy水平随年龄增加而增加,同时HH与血管性痴呆和/或变性性痴呆有关。     

三列凹顶藻中倍半萜成分的研究

目的从三列凹顶藻Laurenciatristicha中寻找具有多样性结构的倍半萜化学成分,供药理活性筛选。方法采用凝胶柱色谱、硅胶柱色谱、重结晶和高效液相色谱等方法进行分离;借助包括一维和二维NMR等波谱方法和X-单晶衍射鉴定化合物的结构;用MTT法对得到的化合物进行细胞毒活性评价。结果分离得到5个倍半萜类化合物,分别鉴定为海兔阿普里素(aplysin,)、海兔阿普里醇(aplysinol,)、去溴海兔阿普里醇(debro-moaplysinol,)、凹顶藻联苯(laurebiphenyl,)、约翰斯顿醇(johnstonol,);在人肿瘤细胞株HCT-8、Bel-7402、BGc-823、A549和HeLa模型上,化合物对所有细胞株均显示毒性,化合物对HeLa细胞显示中等强度的细胞毒活性,其他化合物对所有细胞株均无明显毒性,IC50均大于10.0μg/mL。结论化合物~均为首次从三列凹顶藻中得到,化合物对HeLa细胞具有中等强度的选择性细胞毒活性,化合物对所有细胞株均显示毒性。     

山药粗多糖的提取工艺

对鲜山药中水溶性粗多糖的提取工艺进行了研究,通过单因素试验和L9（34）正交试验,研究了料液比、提取温度、时间和乙醇体积分数对粗多糖得率的影响,极差分析及方差分析结果表明提取温度和料液比是影响山药粗多糖提取的主要因素,较优的工艺为料液比1 g：9 mL,温度50 ℃,时间2.5 h,乙醇体积分数75%,在此工艺条件下,鲜山药粗多糖得率为0.2449%（以鲜山药质量计）.     

阿尔茨海默病患者的执行功能障碍

目的了解阿尔茨海默病(A lzhe im er d isease,AD)患者执行功能损害状况及对于生活能力的影响,探讨执行功能障碍与记忆等AD常见认知功能损害的相关性。方法运用神经心理学测验的方法对40例AD患者及30例轻度认知功能损害(m ild cogn itive impairm ent,MC I)患者进行执行功能、记忆及其他认知功能检查,同时进行生活能力评定。另外选择40名健康老人作对照。结果AD组的执行功能测验成绩均显著低于健康对照组(P<0.01),其中额叶功能评定量表(FAB)(5.29±2.47)分,执行性画钟作业(CLOX1)(4.63±3.56)分,Stroop测验错误次数(Stroop1)(14.17±8.99)分,词语流畅性测验(RVR)(17.56±10.51)分。除Stroop测验反应时间(Stroop2)外,MC I组的其他执行功能测验成绩显著低于健康对照组(P<0.05),其中FAB为(7.67±2.44)分,CLOX1为(7.86±3.78)分,Stroop1为(7.21±8.07)分,RVR为(30.86±8.38)分。用多元逐步回归方法分析不同认知功能对生活能力的影响,结果为反映执行功能的FAB测验成绩处于第一位,独立与操作性日常生活能力(IADL)相关(β=-0.778,t=-7.079,P<0.01)。各项执行功能测验与年龄相关性不明显(r=0.026~0.250,P>0.05),与简易精神状态量表(MMSE)、记忆测验成绩相关性好(r=0.438~0.786,P<0.01)。结论AD患者具有明显的执行功能障碍;在尚未到达痴呆水平的MC I阶段也可发现执行功能损害。执行功能和整体认知功能及记忆等认知域功能具有良好的相关性。AD患者的执行功能障碍是导致生活能力下降的重要因素。     

胃癌前哨淋巴结临床意义的研究

目的 观察胃癌前哨淋巴结的分布，探讨其临床意义。方法 回顾性分析288例胃癌前哨淋巴结术中染色后显影的范围及特征。术中向肿瘤边缘的正常胃壁浆膜下肌层、黏膜下层注射亚甲蓝，观察淋巴结显影的情况；切取各站淋巴结行病理检查。结果 288例胃癌术后病理诊断为T1期102例，T2期126例，T3期60例。术中成功显影270例，阳性率为93．8％。102例患者有淋巴结转移，其中前哨淋巴结（SNs）与非前哨淋巴结（non—SNs）均有转移者66例，仅前哨淋巴结有转移者18例，仅非前哨淋巴结有转移者18例。结论 通过前哨淋巴结，术中能准确预测胃癌淋巴结转移状况。在手术治疗淋巴结转移阴性的胃癌患者中，前哨淋巴结术中标识有望免除常规淋巴清扫。